Method for distinguishing normal and transformed cells using G1 kinase inhibitors
A G[sub 1] phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G[sub 1] phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G[sub 1] cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G[sub 1] phase, suggesting that such G[sub 1] phase kinase inhibitors may form an effective adjuvant for use with chemotherapeutic agents in cancer therapy for optimizing the killing dose of chemotherapeutic agents while minimizing undesirable side effects on normal cells.
- DOE Contract Number:
- W-7405-ENG-36
- Assignee:
- Dept. of Energy, Washington, DC (United States)
- Patent Number(s):
- US 5185260; A
- Application Number:
- PPN: US 7-751855
- OSTI ID:
- 6282503
- Resource Relation:
- Patent File Date: 29 Aug 1991
- Country of Publication:
- United States
- Language:
- English
Similar Records
Method for distinguishing normal and transformed cells using G1 kinase inhibitors
G{sub 1} arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637
Related Subjects
ANIMAL CELLS
CELL TRANSFORMATIONS
ENZYME INHIBITORS
SPECIFICITY
PHOSPHOTRANSFERASES
CELL CYCLE
CELL KILLING
CHEMOTHERAPY
MAMMALS
NEOPLASMS
ANIMALS
DISEASES
ENZYMES
ORGANIC COMPOUNDS
PHOSPHORUS-GROUP TRANSFERASES
PROTEINS
THERAPY
TRANSFERASES
VERTEBRATES
550200* - Biochemistry